Načítá se...
Impact of nicorandil in angina: subgroup analyses
Aims: IONA (impact of nicorandil in angina) is a randomised, double blind, placebo controlled trial of nicorandil, with a target dose of 20 mg twice daily. The consistency of benefits seen in subgroups is reported. Methods: The primary composite end point of the study was coronary heart disease deat...
Uloženo v:
| Médium: | Artigo |
|---|---|
| Jazyk: | Inglês |
| Vydáno: |
Copyright 2004 by Heart
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1768587/ https://ncbi.nlm.nih.gov/pubmed/15547020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/hrt.2003.026310 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|